An Eight-Week, Randomized, Double-Blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus.

Trial Profile

An Eight-Week, Randomized, Double-Blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aliskiren (Primary) ; Ramipril
  • Indications Essential hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 06 Nov 2012 Planned number of patients (846) added as reported by European Clinical Trials Database.
    • 10 May 2011 New source from European Clinical Trials Database identified (EudraCT2004-001062-40) and integrated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top